Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.

[1]  K. Poplawska,et al.  170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study , 2022, Journal of Cystic Fibrosis.

[2]  S. McColley,et al.  Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype , 2021, Pediatric pulmonology.

[3]  M. Griese,et al.  Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial , 2020, American journal of respiratory and critical care medicine.

[4]  S. Rowe,et al.  Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. , 2019, American journal of respiratory and critical care medicine.

[5]  C. Teneback,et al.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.

[6]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[7]  Christine Pierre,et al.  Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. , 2019, Current problems in cardiology.

[8]  C. Goss,et al.  The future of cystic fibrosis care: a global perspective. , 2020, The Lancet. Respiratory medicine.

[9]  F. van Goor,et al.  VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles , 2018, The New England journal of medicine.

[10]  V. Uttamsingh,et al.  Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[11]  M. Boyle,et al.  Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  F. van Goor,et al.  Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  P. Palange,et al.  Cystic fibrosis , 2016, The Lancet.

[14]  S. Harbeson,et al.  WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco® in Phase I clinical studies , 2016 .

[15]  C. Goss,et al.  Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[16]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[17]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[18]  W. Trager,et al.  The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. , 2003, Drug metabolism and disposition: the biological fate of chemicals.